BeOne Medicines (BEIGF) Other Non-Current Assets (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Other Non-Current Assets data on file, last reported at $104.2 million in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $104.2 million, down 30.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $104.2 million (down 30.45% YoY), and the FY2025 annual result was $102.4 million, down 36.18% from the prior year.
• Other Non-Current Assets improved to $104.2 million in Q1 2026 per BEIGF's latest filing, from $102.4 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $201.2 million in Q3 2024 and troughed at $3.9 million in Q2 2022.
• A 5-year average of $123.1 million and a median of $140.6 million in 2022 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets plunged 60.32% in 2022, then jumped 2391.61% in 2023.
• A 5-year view of Other Non-Current Assets shows it stood at $75.1 million in 2022, then soared by 66.89% to $125.4 million in 2023, then advanced by 28.02% to $160.5 million in 2024, then plunged by 36.18% to $102.4 million in 2025, then grew by 1.78% to $104.2 million in 2026.
• Business Quant data shows BEIGF's Other Non-Current Assets at $104.2 million in Q1 2026, $102.4 million in Q4 2025, and $136.2 million in Q3 2025.